References
- 1Tota JE, Chevarie-Davis M, Richardson LA, Devries M, Franco EL. Epidemiology and burden of HPV infection and related diseases: Implications for prevention strategies. Prev Med. 2011; 53(Suppl 1): S12–21. DOI: 10.1016/j.ypmed.2011.08.017
- 2Parkin DM, Bray F. Chapter 2: The burden of HPV-related cancers. Vaccine. 2006; 24(Suppl 3): 11–25. DOI: 10.1016/j.vaccine.2006.05.111
- 3WHO/ICO Information Centre on HPV and Cervical Cancer (HPV Information Centre). Human papillomavirus and related cancers in Nigeria, summary report. 2010.
- 4Federal Ministry of Health (FMOH).
National strategic health development plan 2010–2015 . 2010; Abuja, Nigeria: FMOH. - 5Clifford G, Franceschi S, Diaz M, Munoz N, Villa LL. Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases. Vaccine. 2006; 24(Suppl 3): S26–34. DOI: 10.1016/j.vaccine.2006.05.026
- 6Arie S. Global HPV vaccination. BMJ. 2011; 342:
d1042 . DOI: 10.1136/bmj.d1042 - 7World Health Organization.
Comprehensive cervical cancer: A guide to essential practice . Geneva: WHO Press; 2014. - 8Mohammadi D. The final push for polio eradication? Lancet. 2012; 380(9840): 460–462. DOI: 10.1016/S0140-6736(12)61279-3
- 9Bruni L, Albero G, Serrano B, et al.
Human Papillomavirus and Related Diseases in Nigeria . Summary Report 10 December 2018. ICO/IARC Information Centre on HPV and Cancer (HPV Information Centre).https://hpvcentre.net/statistics/reports/NGA.pdf (Accessed May 2019). - 10Ajzen I.
From intentions to actions: A theory of planned behavior . In: Action control. Vol Part I. SSSP Springer Series in Social Psychology. Berlin, Heidelberg: Springer; 1985. DOI: 10.1007/978-3-642-69746-3_2 - 11Godin G, Kok G. The theory of planned behavior: A review of its applications to health-related behaviors. Am J Health Promot. 1996; 11(2): 87–98. DOI: 10.4278/0890-1171-11.2.87
- 12Prislin R, Nader PR, De Guire M, et al. Physicians’ immunization knowledge, attitudes, and practices: A valid and internally consistent measurement tool. Am J Prev Med. 1999; 17(2): 151–152. DOI: 10.1016/S0749-3797(99)00054-9
- 13University of California, San Francisco. Guidance on research topics and issues, the Committee on Human Research: Exempt certification and non-human subject research.
http://www.research.ucsf.edu/chr/Guide/chrExemptApp.asp# (4 March 2013). - 14Wage Indicator Network. Living Wage Series – Nigeria – December 2018 – In Naira, per Month.
https://wageindicator.org/salary/living-wage/nigeria-living-wage-series-december-2018 (Accessed: August 2019). - 15Black E, Richmond R. Prevention of cervical cancer in sub-Saharan Africa: The advantages and challenges of HPV vaccination. Vaccines. 2018; 6(3): 61. DOI: 10.3390/vaccines6030061
- 16Ogunbode OO, Ayinde AO. Awareness of cervical cancer and screening in a Nigerian female market population. Ann Afr Med. 2005; 4(4): 160–163.
- 17Ayinde OA, Omigbodun AO. Knowledge, attitude and practices related to prevention of cancer of the cervix among female health workers in Ibadan. J Obstet Gynaecol. 2003; 23(1): 59–62. DOI: 10.1080/0144361021000043272
- 18Ayinde OA, Omigbodun AO, Ilesanmi AO. Awareness of cervical cancer, Papanicolaou’s smear and its utilisation among female undergraduates in Ibadan. Afr J Reprod Health. 2004; 8(3): 68–80. DOI: 10.2307/3583394
- 19Gharoro EP, Ikeanyi EN. An appraisal of the level of awareness and utilization of the pap smear as a cervical cancer screening test among female health workers in a tertiary health institution. Int J Gynecol Cancer. 2006; 16(3): 1063–1068. DOI: 10.1111/j.1525-1438.2006.00579.x
- 20Nyambe A, Kampen JK, Baboo SK, Van Hal G. Knowledge, attitudes and practices of cervical cancer prevention among Zambian women and men. BMC Public Health. 2019; 19(1): 508. DOI: 10.1186/s12889-019-6874-2
- 21Umeh IB, Nduka SO, Ekwunife OI. Mothers’ willingness to pay for HPV vaccines in Anambra state, Nigeria: A cross sectional contingent valuation study. Cost Effectiveness and Resource Allocation. 2016; 14(8). DOI: 10.1186/s12962-016-0057-0
- 22Gavi, the Vaccine Alliance. Countries approved for support – results & evidence – GAVI alliance. Updated 2019.
http://www.gavialliance.org/results/countries-approved-for-support/ (Accessed May 2019). - 23Gulland A. Drug companies agree to cut price of HPV vaccine to developing countries to increase accessibility. BMJ. 2013; 346:
f3025 . DOI: 10.1136/bmj.f3025